Soligenix Halts Phase 3 HyBryte Trial for Futility, Holds $6M Cash Runway
SNGX•Soligenix halted its pivotal Phase 3 FLASH2 trial of HyBryte after an interim analysis found no efficacy signal at 18 weeks, despite previous positive results at six weeks. The company reported a $2.8M net loss for Q1 2026 and holds $6.0M cash, providing runway into Q2 2027.
1. FLASH2 Trial Halt and Data Analysis
The Data Monitoring Committee recommended halting the pivotal Phase 3 FLASH2 trial of HyBryte after an interim efficacy analysis showed no statistically significant lesion reduction at the 18-week mark, contrasting with earlier positive six-week study results. Management will analyze the full dataset to identify potential responder subsets and plan follow-up discussions with regulatory agencies.
2. Q1 Financial Results and Cash Runway
Soligenix posted a net loss of $2.8 million ($0.28 per share) for Q1 2026, down from $3.0 million a year earlier, driven by reduced operating expenses. The company ended the quarter with $6.0 million in cash, supporting operations into the second quarter of 2027.
3. Pipeline Review and Strategic Options
With the FLASH2 setback, Soligenix is evaluating all strategic options, including mergers, acquisitions, and advancement of SGX945 for Behçet’s Disease, which holds orphan and PIM designations after promising Phase 2 efficacy. The firm also noted completion of a Phase 2a trial for SGX302 in psoriasis with favorable safety outcomes.
